🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Ultra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating Endometriosis

RecruitingPhase 4Ages 18 Years - 39 YearsFemaleLi-jun Ding
NCT07696351 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Deep infiltrating endometriosis is a severe form of endometriosis that may reduce fertility and negatively affect pregnancy outcomes after assisted reproductive treatment. Gonadotropin-releasing hormone agonist pretreatment may suppress endometriotic lesions, reduce inflammation, and improve endometrial receptivity, but its benefit before frozen-thawed embryo transfer remains uncertain. This randomized controlled study will evaluate whether ultra-long GnRH-a pretreatment before hormone replacement therapy improves clinical pregnancy outcomes in patients with deep infiltrating endometriosis undergoing their first frozen-thawed embryo transfer cycle. Eligible participants will be randomly assigned to either the GnRH-a pretreatment group or the control group. Participants in the GnRH-a group will receive two injections of long-acting GnRH-a before hormone replacement therapy for endometria

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Female patients aged 18 to 39 years. 2. Diagnosed with deep infiltrating endometriosis by ultrasound at the study center. 3. Undergoing the first frozen-thawed embryo transfer cycle with hormone replacement therapy for endometrial preparation. 4. Having at least one good-quality frozen embryo. 5. Willing to participate in this randomized controlled study of GnRH-a pretreatment for deep infiltrating endometriosis and able to personally sign the written informed consent form. Exclusion Criteria: 1. Abnormal chromosomal karyotype. 2. Other uterine diseases or conditions that may affect uterine cavity morphology or pregnancy outcomes, including intrauterine adhesions affecting the uterine cavity, intramural uterine fibroids, moderate to severe adenomyosis, congenital uterine malformation, endometrial tuberculosis, or endometrial thickness less than 8 mm on the transformation day. 3. Recurrent implantation failure. 4. Contraindications to hormone replacement therapy or long-acting GnRH-a treatment. 5. Osteoporosis or depressed mood. 6. Currently participating in another clinical study. 7. Unable to adhere to study visits and follow-up, or planning to receive other treatment during the follow-up period.
💊

What it tests

  • Triptorelin (GnRH agonists)
  • Hormone Replacement Therapy (HRT)
📍

Where

1 site
The Affiliated Drum Tower Hospital of Nanjing University Medical School
Nanjing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy